Replimune (REPL) Group announced a proposed public offering of $125 million of shares of its common stock and pre-funded warrants to purchase shares of common stock. All securities in the offering will be offered by Replimune. In addition, Replimune intends to grant the underwriter a 30-day option to purchase up to an additional $18.75 million of securities from Replimune at the public offering price, less the underwriting discounts and commissions.Leerink Partners is acting as sole bookrunning manager for the proposed offering. The proposed offering is subject to market and other customary closing conditions.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REPL:
- Amazon invests $4B more in Anthropic, Gap reports Q3 beat: Morning Buzz
- Replimune price target raised to $18 from $14 at BMO Capital
- Closing Bell Movers: Gap jumps 15% after Q3 earnings beat, guidance raise
- Replimune Group Advances Cancer Treatment with FDA Submission
- Replimune submits RP1 BLA to FDA, receives breakthrough therapy designation
Questions or Comments about the article? Write to editor@tipranks.com